SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): May 15, 2009
______________
Neuralstem, Inc.
(Exact
name of registrant as specified in Charter)
Delaware |
000-1357459 |
52-2007292 |
||
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) |
(IRS Employer Identification No.) |
9700 Great Seneca Highway, Rockville, Maryland 20850 |
(Address of Principal Executive Offices) |
(301) 366-4841
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: (see General Instruction A.2. below):
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure.
On May 15, 2009, Neuralstem, Inc. (“the Company”) issued a press release responding to certain statements issued earlier on May 15, 2009 by StemCells, Inc. A copy of the press release is attached to this report as Exhibit 99.1.
The information contained in this Current Report on Form 8-K and the
exhibits attached hereto shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall such information or such exhibits be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing. The information set forth
in or exhibits to this Form 8-K shall not be deemed an admission as to
the materiality of any information in this report on Form 8-K that is
required to be disclosed solely to satisfy the requirements of
Regulation FD.
Item
9.01 Financial Statements and Exhibits.
Exhibit |
Description |
99.1 | Press Release Dated May 15, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
NEURALSTEM, INC. |
|||
|
|
By: |
/s/ I. Richard Garr |
I. Richard Garr |
|||
Chief Executive Officer |
|||
Dated: |
May 15, 2009 |